ALASKA MEDICAID
Prior Authorization Criteria

Fintepla®
(fenfluramine)

FDA INDICATIONS AND USAGE[1]

Fintepla® is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. Fenfluramine increases extracellular serotonin levels and acts as both a serotonergic 5-HT2 receptor agonist and σ1 receptor antagonist.

APPROVAL CRITERIA[1,2,3]

1. Patient is 2 years of age or older **AND;**
2. The medication is being prescribed by or in consultation with a neurologist **AND;**
3. Patient has a confirmed diagnosis of seizures associated with Dravet syndrome **AND;**
4. ICD-10 code is provided and written on the prescription **AND;**
5. The patient has undergone an echocardiogram prior to initiating therapy **AND;**
6. The patient has tried for at least one month and failed or contraindication to TWO or more of the following:
   a. valproate
   b. clobazam
   c. topiramate
   d. levetiracetam

DENIAL CRITERIA[1,3]

1. Failure to meet approval criteria **OR;**
2. Patient has moderate to severe renal impairment **OR;**
3. Patient has hepatic impairment **OR;**
4. Concomitant use of, or within 14 days of the administration of monoamine oxidase inhibitors.

CAUTIONS[1]

- Patients should be advised that the drug can cause decreased appetite and decreased weight.
- Monitor for somnolence and sedation. Patients should be advised not to drive or operate machinery.
- Monitor for suicidal behavior and ideation.
- Serotonin Syndrome has been observed particularly with concomitant administration of other serotonergic drugs.
- Blood pressure should be monitored during treatment.

DURATION OF APPROVAL

- Initial Approval: up to 3 months
- Reauthorization Approval: up to 12 months

QUANTITY LIMIT

- Up to 12ml per day (max daily dose is 26mg)
- 360ml per 30 days

REFERENCES / FOOTNOTES:

1. Fintepla [prescribing information]. Emeryville, CA: Zogenix Inc.; June 2020.
2. Dravet Foundation – Dravet Syndrome. Available at: https://www.dravetfoundation.org/what-is-dravet-syndrome/. Accessed on December 3, 2020.
3. Cross JH, Caraballo RH, Nabbout R, Vigevano F, Guerrini R, Lagae L. Dravet syndrome: Treatment options and management of prolonged seizures. Epilepsia. 2019;60(S3):S39–S48.